Showing posts with label HIV. Show all posts
Showing posts with label HIV. Show all posts

5/17/2013

Malaria and HIV Spike as Greece Cuts Healthcare Spending

A pharmacist arranges drugs in a pharmacy in Athens on March 1, 2012.

Πηγή: The Atlantic
By MICHAEL SCATURRO
May 15 2013

One day in late March, European finance and health ministry officials met at the OECD's Paris office to discuss how healthcare systems are faring in times of austerity.

On the second day of the two-day conference, Greek finance ministry official Evdoxia Andrianopoulou read from a series of brown-colored PowerPoint slides riddled with details of attrition and savings. Greece's cuts were deep, of the sort commonly seen in a corporate turnaround - but rarely on a government's balance sheet, and almost never to healthcare expenses.

The takeaway from the meeting - according to two people who attended it - was that Greek officials knew that these huge cuts would result in the curtailing of essential services for their people. But the officials were working under the stress of having to meet a financial target set by their tri-party group of creditors: the European Commission, the International Monetary Fund, and the European Central Bank. And so they delivered.

According to an Austrian finance ministry official who attended the meeting, participants in the room "were in a state of shock" after Andrianopoulou concluded her talk. Another attendee who asked that he not be quoted said "a pin-drop silence" filled the room.

Meanwhile, across the Channel in London, academics were preparing to release a study in "The Lancet" on the healthcare crisis that has followed deep budget cuts in Southern Europe.

One of that work's principal researchers, David Stuckler of Oxford University, warned that not just Greece, but also Spain and Portugal, faced a potential healthcare disaster due to their own steep budget cuts.

Yet of the three crisis-stricken countries, Greece seems to have suffered the most.

"Greece is an example of perhaps the worst case of austerity leading to public health disasters," Mr. Stuckler explained in a telephone interview.

"After mosquito spraying programs were cut, we've seen a return of malaria, which the country has kept under control for the past four decades. New HIV infections have jumped more than 200 percent," he noted.

Malaria returned because municipal governments lacked the funds to spray against mosquitoes. HIV spiked because government needle exchange programs ran out of clean syringes for heroin addicts. By Stuckler's estimate, the average Greek junkie requires 200 clean needles in a given year.

"But now they're only getting three a year each," Stuckler said.

Athenian drug addicts sharing needles or malaria-carrying mosquitoes biting Spartans have put Greece in the media spotlight over the past few months. But a decidedly less headline-grabbing fact is this: cuts taken over the last two years could look even worse a few years from now.

"The thing about healthcare systems," the OECD's Ankit Kumar explained in a telephone interview, "Is you cut the money today, and start to see the cuts' impact at least three to four years from now. You know that people aren't getting their medications. But it takes a couple of years before this manifests itself in high levers of sickness, fewer people being able to work, and more people facing shorter lives. Given the consequences of what has happened in Greece, these outcomes are just going to get worse and worse."

Some experts have suggested that Greece's budgetary ax fell unduly hard on its healthcare sector, which was slated to grow at around 4 percent annually, but which has instead been jolted by a series of wage freezes, firings, and drug rationing programs. Economists around the world warned of the cuts' consequences - but it was the Greeks themselves who opted for deep gashes to their healthcare system.

"IMF doesn't say 'you have to cut 10 percent of your economy, but you can't close hospitals or schools.' Where the cuts are made remains a country's sovereign right," Kumar explained.

This spring has been an important time for healthcare research in Europe because data now confirm - as if there was any doubt - that in healthcare, too, the gulf between Europe's north and its south has continued to widen.

Last year, while Greece went about adjusting to its new slimmed-down healthcare reality, German's ministry of health contacted the OECD for its help in studying the exact opposite problem. German healthcare costs were ballooning, but only a third of the growth could be linked to Germans becoming sicker or aging.

The OECD's research on Germany was published this spring, at nearly the same time that the full picture of Greece's healthcare tragedy came into form.

OECD researchers compared Germany to its peers, and came to a simple conclusion: German doctors seem to be prescribing treatments, operations, and hospital stays more often than might be medically necessary. That this is occurring while Germany's neighbors just a two-hour plane ride away in Athens face the worse healthcare and societal crisis in their history only underscores the much publicized idea that Europe is growing apart.

One statistic was especially telling: the OECD average for hospital beds per 1,000 patients sits at 4.9; in the case of Germany, it's 8.3. France has 6.4, while the U.S. has 3.1.

"The difference in the medical science between the United States, Germany, and France is not so great that it can justify 70 percent higher numbers in Germany than the OECD average," Kumar said.

Kumar and his co-author, Michael Schoenstein, theorized that because Germany has more hospitals than it needs, doctors and hospitals appear to be steering patients towards more expensive in-patient procedures and then tacking on multiple night hospital stays in order to fill hospital beds and submit payments to Germany's essentially unlimited system of insurance reimbursements.

"These are big institutions that want to be busy," Kumar said. "After investing millions, and in some cases billions of dollars, into the infrastructure, no one wants to have these institutions running at 60 percent. They know that if hospitals aren't full, someone's going to point the finger and say 'hold on a second, you're running at 60 percent capacity regularly, why do you have all of these empty beds, we need to get rid of that.'"

***

The OECD lacks clear data on how many Greeks have been denied medical care during the country's economic crisis. But anecdotal reports have shown that people are being deprived care.

The New York Times reported that "breast cancer patients often have to wait three months now to have tumors removed" and that at least 2,000 patients in need of bypass surgery haven't been scheduled for procedures.

Could the solution to Greeks' healthcare crisis be to send patients north to Germany's hospitals? With Europe's common market, citizens' freedom of movement, couldn't Greeks just fly north for treatment?

"Yes, EU citizens can travel to other EU countries for treatment," OECD's Michael Schoenstein explained, "But for planned treatments like cancer treatments, they need prior approval from their healthcare insurers at home. It's theoretically possible, but practically very difficult."



11/30/2012

Health officials tell Greece to act fast to control HIV



Πηγή: Reuters
By Kate Kelland
Nov 30 2012

A spiraling outbreak of HIV in debt-stricken Greece could run out of control unless urgent action is taken, European health officials said on Friday.

The European Centre for Disease Prevention and Control (ECDC) said infections with the AIDS-causing virus among drug users and other high-risk groups were rising fast, and that a failure to act would mean far higher costs in future.

ECDC director Marc Sprenger was in Athens on Friday visiting hospitals and needle exchanges. He said he would tell officials that free syringes and methadone programs must be stepped up, and testing and treatment for the human immunodeficiency virus made available to all.

"Immediate concerted action is needed in order to curb and eventually stop the current outbreak," he told Reuters as the ECDC published a report on Greece's HIV problem.

Since 2009, recession in Greece has reduced economic output by a fifth and sent unemployment to a record high.

The healthcare system is under extreme pressure, making it harder for the poor, unemployed or homeless to get treatment.

The ECDC said it was unclear how much Greece's debt crisis is contributing to the HIV outbreak, but it was evidently having "a significant social and health impact". There were fears in Athens that "HIV treatment services have reached a ceiling" because of a leap in case numbers in 2012.

While Greece has only 7.4 HIV infections per 100,000 people, compared to 10 per 100,000 in Britain or 27.3 in Estonia, rates have soared since 2011 in high-risk groups such as drug users.

From 2007 to 2010, there were only 10 to 15 cases a year of HIV infection in injecting drug users.

But during 2011, there were 256 such cases - or 27 percent of the total. Another 314 drug use HIV cases were reported between January and August 2012, bringing the total HIV cases for the year to August to 768.

Combination drugs can give patients with HIV near-normal life expectancy, but the drugs must be taken for life, and cost 10,000 to 22,000 euros ($13,000 to $28,500) a year.

"If a scale-up (in prevention and testing) is not achieved, it's likely that HIV transmission among people who inject drugs in Athens will continue and even accelerate - and could eventually spread," Sprenger said.

"The cost of prevention ... will be significantly less than the provision of treatment to those who become infected."

The ECDC said waiting times for methadone programs in Athens were more than seven years in August 2010, and only around seven syringes a year were given to each drug user.

Efforts by authorities to address this have now brought waiting lists down below four years and increased the number of syringes to 15 a year in 2011 and an expected 45 in 2012, but this is well below the international standard of 200 needles.

Rates of other health problems such as depression and suicide have been rising in Greece, which is also battling the re-emergence of mosquito-borne diseases such West Nile Virus and malaria.



3/15/2012

Greece on the breadline: HIV and malaria make a comeback

Doctors, nurses and paramedics clash with riot police outside the health ministry last May during a protest against cuts. 

Πηγή: The Guardian
By Jon Henley
March 15 2012

The incidence of HIV/Aids among intravenous drug users in central Athens soared by 1,250% in the first 10 months of 2011 compared with the same period the previous year, according to the head of Médecins sans Frontières Greece, while malaria is becoming endemic in the south for the first time since the rule of the colonels.

Reveka Papadopoulos said that following savage cuts to the national health service budget, including heavy job losses and a 40% reduction in funding for hospitals, Greek social services were "under very severe strain, if not in a state of breakdown. What we are seeing are very clear indicators of a system that cannot cope."

The heavy, horizontal and "blind" budget cuts coincided last year with a 24% increase in demand for hospital services, she said, "largely because people could simply no longer afford private healthcare. The entire system is deteriorating."

The extraordinary increase in HIV/Aids among drug users, due largely to the suspension or cancellation of free needle exchange programmes, has been accompanied by a 52% increase in the general population.

"We are also seeing transmission between mother and child for the first time in Greece," she said. "This is something we are used to seeing in sub-Saharan Africa, not Europe. There has also been a sharp increase in cases of tuberculosis in the immigrant population, cases of Nile fever – leading to 35 deaths in 2010 – and the reappearance of endemic malaria in several parts of Greece, notably the south."

According to Papadopoulos, such sharp increases in communicable diseases are indicative of a system nearing breakdown. "The simple fact of the reappearance of malaria, with 100-odd cases in southern Greece last year and 20 to 30 more elsewhere, shows barriers to healthcare access have risen," she said. "Malaria is treatable, it shouldn't spread if the system is working."

MSF has been active in Greece for more than 20 years, but until now has largely confined its activities to emergency interventions after natural disasters such as earthquakes, and providing care to the most vulnerable groups in the community, including immigrants.

It is now focusing on supporting the public health sector, providing emergency care in shelters for the homeless and improving the overall response to communicable diseases. Papadopoulos, who spent 17 years abroad with MSF and returned to her native Greece three years ago, sees hope among the rubble. "What keeps me going is an increasingly strong sense of solidarity among the Greek people," she said. "Donations to MSF, for example, have of course gone down with the crisis, but donors keep giving, they remain active."

She sees a refreshing new phenomenon of self-organisation and social action. "In the past year of this crisis I have seen really encouraging, really exciting things happening – people are seeing the power of organising themselves. We have to support them."


9/13/2011

Analysis: Legal case in India threatens HIV drug access for poorest



Πηγή: The Bureau
by Melanie Newman
September 12th, 2011


A technical case going through the Supreme Court in India is being carefully watched by aid agencies and other human rights organisations, who claim it could have severe consequences for the supply of lifesaving drugs to the developing world.

More than 90% of drugs used to treat children with AIDS in Africa come from Indian generic manufacturers, according to the medical NGO Medicins Sans Frontieres. And if the Swiss pharmaceutical giant Novartis wins a case it has brought against the Indian government, MSF fears that supply could dry up.

Novartis is seeking patent protection for its leukaemia drug Glivec, whose patent has expired in India. It is challenging India’s interpretation of a section of the nation’s patent law — Section 3(d) — which prevents ‘evergreening’.
India is literally the lifeline of patients in the developing world, especially in the poorest parts of Africa…If Sec. 3(d) is overturned, it means any meaningful effort to make these vital medicines available will be put in jeopardy.

Turning old into new


Evergreening is a common method used by drug companies to extend the life of their patents. They make slight alterations to the basis molecule every few years and apply for fresh patents for the amended versions, which then prevents generic copies of the drugs being made.

But in India, applications to patent many new forms of old drugs, including HIV/AIDS and tuberculosis treatments have failed. Under Indian law a new patent will not be granted unless the company can prove the changes make the drug significantly more effective.

The Novartis challenge, currently being heard in the Supreme Court, could effectively water down Section 3(d). MSF believes the cost of drugs to the developing world would spiral as other pharmaceutical companies sought to extend the patents for drugs used to treat diseases such as HIV/AIDS and TB.

It is an argument that Novartis wholeheartedly rejects. ‘Currently available generic drugs launched in India before 2005–including HIV/AIDS medicines and generic versions of Glivec – will continue to be available under the transition clause in the Indian patent law regardless of the legal outcome of our case,’ it says.

Leena Menghaney of MSF says: ‘India is literally the lifeline of patients in the developing world, especially in the poorest parts of Africa…If Sec. 3(d) is overturned, it means any meaningful effort to make these vital medicines available will be put in jeopardy.’

Novartis has argued that it provides thousands of patients in developing countries with free Glivec through the Glivec International Patient Assistant Programme (GIPAP). In 2008 CEO Daniel Vasella pointed out that 8,400 patients in India had received the drug through this programme – by 2011 this had risen to more than 13,000.
More than 90% of drugs used to treat children with AIDS in Africa come from Indian generic manufacturers.

But the New York Times‘ 2003 investigation into GIPAP criticised the programme’s operation in India. ‘Novartis began its donations of Glivec with a warning that it would halt the program if the government let local companies eat into its profits by selling generic versions of the drug,’ the paper reported.

‘Hundreds of Indian cancer patients got Glivec free, and commercial sales soared, as well. But after India cleared generic Glivec for sale, Novartis made good on its threat last month, saying it would leave it to Indian companies to meet the needs of the indigent.’

In wealthier countries, the paper said Novartis had encouraged people who received the drug for free to become Glivec advocates, pressuring their government to pay for it.

GIPAP was restored in India but as Amit Sen Gupta of the People’s Health Movement points out, there are some 100,000 patients in India with chronic myeloid lukaemia, with 20,000 new cases diagnosed every year. Philanthropy, he suggests, is no substitute for generic medicines.

Too much at stake


‘What Novartis is challenging in the Supreme Court of India is not just the order denying the company a patent for Glivec. Novartis is challenging the very heart of the Indian Patent Act and its attempt to balance the rights of patent holders with the needs of the Indian people for access to treatment that is affordable,’ he says. It is a case, he adds, that Novartis ‘must not win’.

Novartis, meanwhile, insists that generics alone aren’t the solution to the problems faced by the poorest in access medicines. ‘Even our critics recognise that generic versions of Glivec are not affordable for the poor in India.

In India, the cost of a year of treatment with generic Glivec is four to five times the average annual income,’ it said. ‘Poor people in developing countries will suffer needlessly until a wide variety of issues such as lack of diagnosis, infrastructure and distribution are solved.’

‘As the second largest manufacturer of generics in the world, Novartis fully understands and recognises the contribution of generics once drug patents expire; our concern is with the non-recognition of intellectual property rights.’

With so much at stake on both sides, it is no wonder the case is being carefully watched around the world.